anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Metabolic Syndrome is characterized by elevated insulin levels, excess body fat in the waist, and elevated levels of glucose and blood pressure, and dyslipidemia. Dyslipidemia in the Metabolic Syndrome is characterized by high levels of triglycerides, low levels of HDL cholesterol, and above average LDL and non-HDL cholesterol. Individuals with elevated LDL cholesterol have traditionally been advised to follow a low fat, high carbohydrate diet. However, research has shown that this diet does not adequately regulate cholesterol levels in individuals with dyslipidemia. A diet consisting of more moderate amounts of fats and carbohydrates may be more beneficial for individuals with the dyslipidemia of the metabolic syndrome. The purpose of this study is to compare the effects of a diet moderate in fat and carbohydrate versus a low fat, high carbohydrate diet on the cholesterol levels, inflammatory factors and vascular response in individuals with metabolic syndrome.

During the initial screening period, participants follow an American Heart Association (AHA) Step 1 diet and cholesterol levels are tested for eligibility under the criteria of the Metabolic Syndrome. Before being randomized, eligible participants have a frequently sampled intravenous glucose tolerance test (FSIVGTT), an abdominal CT scan to measure fat content in two locations and two brachial artery reactivity tests. The FSIVGTT provides information about whether participants are insulin sensitive or insulin resistant. The CT scan measures the fat content in the abdomen and the liver. The brachial artery reactivity tests measure blood flow through the brachial artery in the arm.

This 7-month study consists of two 1-month feeding periods, a rest month between the two feeding periods and a 4-month follow-up diet in a free-living setting. In Month 1, participants are randomly assigned to follow either a moderate fat, moderate carbohydrate diet or a low fat, high carbohydrate diet. Participants receive prepared food at study visits twice a week. Weight and vital signs are measured at each study visit, and blood is collected at baseline, and Weeks 3-1/2 and 4. A brachial artery reactivity test, using an ultrasound to measure artery size and blood flow in the arm, is performed twice in Week 4. In the Month 2 rest period, participants follow an AHA Step 1 diet at home. In Month 3, participants switch to the other diet and all study procedures and evaluations are repeated as in Month 1. During the following Months 4 through 7, participants continue following the second assigned diet, but are responsible for preparing their own food. They meet with a dietician once a week for 1 month to learn how to prepare meals at home. During this 4-month period, blood collection, vital sign measurements, and review of medical history and diet continue at monthly visits. At the end of Month 7, participants again undergo two brachial artery reactivity tests.

As of October, 2010, 148 were screened with 71 eligible to be randomized. Seven discontinued prior to completion and 64 completed the 7 month study. The intervention is complete and analyses are ongoing.
Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
BACKGROUND: Placement of interradicular orthodontic miniscrews poses a potential risk of root damage, including superficial root contact and root fracture. This case report describes the iatrogenic root-injured tooth movement of a 27-year-old male with skeletal Class III malocclusion as nonsurgical orthodontic treatment.
CASE PRESENTATION: An orthodontic miniscrew between the mandibular right first and second molars perforated the distal root of the mandibular first molar. A root fracture was discovered 4 months after miniscrew placement. Owing to the potential risk of ankylosis related to surgical intervention, a direct orthodontic distalizing force was applied towards the fractured distal root segment without additional treatment, resulting in considerable movement of the fractured tooth with maintaining tooth vitality. However, gradual root resorption of a fractured tooth with a separate root segment was observed. The mandibular arch distalization of skeletal Class III malocclusion was successfully performed and retained for 3 years 8 months with stable occlusion.
CONCLUSIONS: This case reveals a clinical remedy when root movement of a tooth with root fracture is indicated. The use of extra-alveolar miniscrews or miniplates can be considered for mandibular arch distalization to prevent potential root injuries caused by miniscrew placement.
CLINICAL TRIAL NUMBER: Not applicable.
PURPOSE: A composition containing Physalis alkekengi var. francheti (Masters) Hort extract is provided to suppress IL-1beta, TNF-alpha, and COX-2 and to prevent and treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains Physalis alkekengi var. francheti (Masters) Hort extract as an active ingredient. The extract is isolated using water, low alcohol of 1-4 carbon atoms, or mixture solvent thereof. A neutraceutical food for preventing and treating inflammatory diseases contains the extract as an active ingredient. The neutraceutical food is used in the form of a tablet, capsule, pill, or liquid.
Aberrant energy metabolism in the brain is a common pathological feature in the preclinical Alzheimer's Disease (AD). Recent studies have reported the early elevations of glycolysis-involved enzymes in AD brain and cerebrospinal fluid according to a large-scale proteomic analysis. It's well-known that astrocytes exhibit strong glycolytic metabolic ability and play a key role in the regulation of brain homeostasis. However, its relationship with glycolytic changes and cognitive deficits in early AD patients is unclear. Here, we investigated the mechanisms by which astrocyte glycolysis is involved in early AD and its potential as a therapeutic target. Our results suggest that Aβ-activated microglia can induce glycolytic-enhanced astrocytes in vitro, and that these processes are dependent on the activation of the AKT-mTOR-HIF-1α pathway. In early AD models, the increase in L-lactate produced by enhanced glycolysis of astrocytes leads to spatial cognitive impairment by disrupting synaptic plasticity and accelerating Aβ aggregation. Furthermore, we find rapamycin, the mTOR inhibitor, can rescue the impaired spatial memory and Aβ burden by inhibiting the glycolysis-derived L-lactate in the early AD models. In conclusion, we highlight that astrocytic glycolysis plays a critical role in the early onset of AD and that the modulation of glycolysis-derived L-lactate by rapamycin provides a new strategy for the treatment of AD.
Relate generally to polymer of the present invention and large molecule, especially, relate to the block polymer that can be used for particle (as nano particle). One aspect of the present invention relates to the method for preparing the nano particle with desired character. In one group of embodiment, described method comprises that generation has the nano particle storehouse of high degree of controlled character, and it can be by mixing two or more large molecules to form by different proportion. One or more in described large molecule can be the polymer conjugates that structure division and biocompatible polymer are puted together. In some cases, described nano particle can comprise medicine. In certain embodiments, the molecular weight of described structure division can be greater than about 1000Da; For example, described structure division can comprise polypeptide or polynucleotides, such as aptamers. Described structure division can also be targeting moiety, imaging moiety, chelating moiety, live part or therapeutic part. Another aspect of the present invention relates to the system and method for producing these polymer conjugates. In some embodiments, the solution that contains polymer is contacted, to form the nano particle that contains described polymer conjugate with liquid (such as immiscible liquids). Other aspects of the present invention relate to use these storehouses method, use or use these polymer conjugates method, promote method, the kit that comprises these polymer conjugates etc. of the application of these polymer conjugates.
PURPOSE:The titled oil emulsion that is prepared by combining prostaglandin E1 (PGE1) with an oil emulsifier for intravenous purpose, thus causing no inactivation in lungs and showing vasodilative and hypotensive actions with stabilized effect and less side-effects. CONSTITUTION:PGE1 is added to an oil emulsifier consisting of 5-50W/V% of soybean oil, 1-50pts.wt. per 100pts.wt. of soybean oil, of phospholipid and an appropriate amount of water, further emulsification aid, stabilizer and high polymer by 0.2-100mug/ml. The resultant preparation is active about 3 times the PGE1-alpha-cyclodextrin clathrate in vasodilation, about 2-9 times in hypotension and 2-30 times in duration. Further, it shows higher focal selectivity to permit effective treatment. There causes no side-effects such as swelling, dull pains, rubor or fervescence, which oftentimes bring about in local application.
Physical therapy is a popular and effective way of treating the pain from sciatica. Myofascial release (MFR) is another useful option for sciatica due to the fact that it focuses the connective tissues of the body, including muscles and the fibrous tissues, often called fascia, encircling the joints.This study will be conducted to compare the Effects of myofacial release technique with and without sciatic nerve slider technique on Pain, Range of Motion and Functional Disability among cricket players with Sciatica. This study will be conducted because, no such evidence found in literature to find out the effects of myofacial release technique with sciatic nerve slider technique for sciatica. Myofacial release technique and sciatic nerve slider technique are useful, because these can reduce patients number of visits for the treatment and are easy to use, feasible and cost effective. The sciatic nerve is the largest nerve in the human body. It is formed at the point where five nerves from the lower back all come together, and stretches all the way from the hips to the bottoms of the feet. When this important nerve becomes compressed, inflamed or irritated, it causes the pain in the lower back and legs known as sciatica. A physical therapist uses a number of proven methods to help relieve sciatic pain. One of the most commonly employed methods is known as myofascial release therapy. Myofascial release is a method that a physical therapist can use to treat many sources of pain that are caused by damage to the nervous system. It involves the therapist using hands-on, manual techniques to release areas of tension and pain in the body. Here are three reasons that myofascial release is an effective tool for treating sciatica.
Hepatocellular carcinoma (HCC) is one of the deadliest cancers. For patients with advanced HCC, liver function decompensation often occurs, which leads to poor tolerance to chemotherapies and other aggressive treatments. Therefore, it remains critical to develop effective therapeutic strategies for HCC. Etiological factors for HCC are complex and multifaceted, including hepatitis virus infection, alcohol, drug abuse, chronic metabolic abnormalities, and others. Thus, HCC has been categorized as a "genomically unstable" cancer due to the typical manifestation of chromosome breakage and aneuploidy, and oxidative DNA damage. In recent years, immunotherapy has provided a new option for cancer treatments, and the degree of genomic instability positively correlates with immunotherapy efficacies. This article reviews the endogenous and exogenous causes that affect the genomic stability of liver cells; it also updates the current biomarkers and their detection methods for genomic instabilities and relevant applications in cancer immunotherapies. Including genomic instability biomarkers in consideration of cancer treatment options shall increase the patients' well-being.
In this group, 10 cmH20 PEEP is applied immediately. Then the "optimal PEEP" is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group.
BACKGROUND: Surgical excision combined with radiotherapy is considered an effective treatment for keloids, while the efficacy and safety of this regimen for huge keloids in patients who need reconstruction after excision is still unclear. Therefore, this study aimed to evaluate the efficacy and safety of surgical excision and reconstruction combined with radiotherapy for huge keloids in a single center with 13 years of experience.
METHODS: All consecutive patients with huge keloids who underwent surgical excision and reconstruction combined with radiotherapy were identified. Demographic information, prior interventions for keloids, parameters and complications, and recurrence rates were documented.
RESULTS: Twenty-one patients (10 males; mean age, 43.19 ± 18.15 years) were included, 14 patients reconstructed with z-plasties, 5 with skin grafts, and 2 with skin flaps. During a mean follow-up of 75 months, one patient developed local necrosis without the need for revision surgery and two patients developed temporary hyperpigmentation. Two patients with the z-plasties suffered partial keloids recurrence, which was healed with corticosteroid injection. No wound infection, hematoma, telangiectasia, or new keloids at donor sites were observed. The overall appearance of reconstructed defects was aesthetically acceptable.
CONCLUSION: Surgical excision and reconstruction combined with radiotherapy may be safe and effective for huge keloids.
Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
The success or failure of smoking cessation is influenced by the quality, intensity and frequency of supportive care. Patients are more likely to quit smoking if they are seen frequently and participate in formal smoking cessation programs. 

The goal of NICOTROL NS therapy is complete abstinence. If a patient is unable to stop smoking by the fourth week of therapy, treatment should probably be discontinued.

Patients who fail to quit on any attempt may benefit from interventions to improve their chances for success on subsequent attempts. Patients who were unsuccessful should be counseled and should then probably be given a "therapy holiday" before the next attempt. A new quit attempt should be encouraged when conditions are more favorable.

Based on the clinical trials, a reasonable approach to assisting patients in their attempt to quit smoking is to begin initial treatment, using the recommended dosage (See DOSAGE AND ADMINISTRATION). Regular use of the spray during the first week of treatment may help patients adapt to the irritant effects of the spray. Dosage can then be adjusted in those subjects with signs or symptoms of nicotine withdrawal or excess. Patients who are successfully abstinent on NICOTROL NS should be treated at the selected dosage for up to 8 weeks, following which use of the spray should be discontinued over the next 4 to 6 weeks. Some patients may not require gradual reduction of dosage and may abruptly stop treatment successfully. Treatment with NICOTROL NS for longer periods has not been shown to improve outcome, and the safety of use for periods longer than 6 months has not been established.

The symptoms of nicotine withdrawal overlap those of nicotine excess (See CLINICAL PHARMACOLOGY, Pharmacodynamics and ADVERSE REACTIONS). Since patients using NICOTROL NS may also smoke intermittently, it is sometimes difficult to determine if patients are experiencing nicotine withdrawal or nicotine excess. Controlled clinical trials of nicotine products suggest that palpitations, nausea and sweating are more often symptoms of nicotine excess, whereas anxiety, nervousness and irritability are more often symptoms of nicotine withdrawal.
A new polymorphic form of (±)7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid is disclosed. The compound has a melting point of 80° C. to 82° C. and is a leukotriene B4 antagonist (“LBA”). The compound is useful for diminishing the adverse effects (e.g. vascular leakage syndrome) of IL-2 treatment.  
     Administering the compound with IL-2 diminishes the adverse effects of IL-2 and preserves or enhances the beneficial effects of LBA administration on a subject, while simultaneously mitigating the adverse effects of using a LBA. The method involves administering an amount of LBA, preferably the new polymorphic form, to a subject undergoing IL-2 treatment, where the amount administered is such that the LBA is maintained in a specified range over the treatment schedule. Also disclosed is an article of manufacture comprising a composition of the new polymorph with labeling instructions for treatment. Also disclosed is a method for preparing a pharmaceutical composition of the new polymorph and a method for preparing the polymorph itself.
The present invention discloses a traditional Chinese medicine oral preparation for treating urinary system infection, which uses nine traditional Chinese medicines of bupleurum root, schisandra, pinkweed, corktree bark, dahurian angelica, dipsacus root, mistletoe, etc. as raw materials. Powdered extract is made through extraction by groups, concentration and dryness, and is uniformly mixed with supplementary materials, and capsules or tablets are made through capsulation, tabletting and coating. The traditional Chinese medicine oral preparation of the present invention has the efficiencies of clearing heat, freeing strangury, promoting urination, alleviating pain, tonifying the kidney and consolidating origin. Pharmacodynamics experiments indicate that the present invention has functions of refrigeration, antisepsis, antiinflammation, diuresis and pain relief. The present invention is used for treating diseases of heat gonorrhea, hot urination, thermalgia, urinary infection, etc. The present invention has the advantages of high effective component content, small administration dosage, significant curative effects, convenience for taking and carrying, easy storage and transportation, stable quality, etc.
Medicaments containing boric acid, sulphuric acid, alcohol, glycerine, distilled water, and geranium essence, are new. The mixture is injected and deposited underneath the tumour, thus isolating the tumour from healthy cells. The tumour may be dressed with cold boiled water for a few days after the operation, until the holes made by the needle have healed. Two weeks later the tumour becomes detached, leaving a clean, neat wound. Used for treatment of external cancers. The method does not suffer from the hazards of radiation treatment nor surgery.
COHORT 1b: Subjects randomized to undergo virtual initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and virtual clinical follow-up after 3 months of clinical intervention. Virtual clinical workup at both the initial and Month 3 follow-up timepoint includes at home completion of International Prostate Symptom Score (IPSS), at home uroflowmetry assessment through use of the Stream Dx device, at home assessment of post void residual (PVR) through use of the DFree device, and at home urinalysis (UA) through use of the TestCard device.
Assistive technology has great potential to help individuals living with chronic health conditions, however devices often fail to align with the unique requirements of users. These results in device abandonment and missed opportunities to benefit people. This exploratory study aims to evaluate the short and longer-term satisfaction, psychological benefit, use and resources involved in co-designed customised assistive devices within a current healthcare service. Individuals with chronic health conditions identified daily living challenges. Eleven individuals completed the trial and were involved throughout the design process. Outcome measures evaluated the impact of the devices provided, healthcare utilisation, help required, and resources used. Nineteen custom assistive devices were produced for twenty-four challenges in daily living identified. At 3-months, eighteen devices were still being used. Daily challenges had become easier for individuals to complete and required less help from informal carers. Individuals were satisfied with the devices and service provided. Improvements in competence, adaptability and self-esteem were sustained long-term. The average clinician's time required to produce a device was 5 h 55 min, with an average cost of £203.79. People with chronic conditions were able to benefit from the co-design process resulting in satisfaction and long-term utilisation of the device, and positive psycho-social benefits. The costs associated with embedding this approach in a healthcare service were calculated. Scaling up the co-design process reduced the associated costs per device compared to previous work. Further work is required to evaluate co-designing across larger samples and explore opportunities to further improve the cost-efficiency.